|

Cell Therapy Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • UNC Lineberger Comprehensive Cancer Center1

Indications

  • Recurrent1
  • Refractory Cancer1
  • Relapse1
  • Head and Neck Cancer1
  • Cancer1

Chapel Hill, North Carolina1 trial

Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC

Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.